PPARG and metabolic dysfunction-associated steatohepatitis: In addition, pirfenidone prevented myocardial steatosis and fibrosis in a mouse model of nonalcoholic steatohepatitis (NASH) by overexpressing PPARα, PPARγ, ACOX1, and CPT1A protein levels and decreasing Timp1, Col I, Col III mRNA levels [59].